To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.
When autocomplete results are available use up and down arrows to review and enter to select.
INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
Study Purpose
The primary objective of this study is to investigate the correlation between changes from
baseline to 52 weeks in Forced Vital Capacity (FVC) [% pred.] and changes from baseline to 52
weeks in dyspnea score [points] or cough score [points] as measured with the living with
pulmonary fibrosis (L-PF) questionnaire over 52 weeks of nintedanib treatment in patients
suffering from chronic fibrosing Interstitial lung disease (ILD) with a progressive phenotype
(excluding idiopathic pulmonary fibrosis (IPF)).
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
No
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
Observational
Eligible Ages
18 Years and Over
Gender
All
More Inclusion & Exclusion Criteria
Inclusion Criteria:
- Adults ≥ 18 years at Visit 1.
- Subjects must be contractually capable and mentally able to understand and follow the
instructions of the study personnel.
- Physician's diagnosis of chronic fibrosing Interstitial lung disease (ILD) with a
progressive phenotype, except Idiopathic pulmonary fibrosis (IPF)
- Initiation of nintedanib as first antifibrotic therapy according to physician´s
decision which has been made as part of routine care prior to and independent of study
inclusion.
- Outpatients not currently hospitalized with a life expectancy > 12 months per
investigator's assessment.
- Written informed consent prior to study participation.
- Current Forced vital capacity (FVC) measurement (taken within the last 3 months)
available in the patient file.
- Women of childbearing potential must take appropriate precautions against getting
pregnant during the intake of nintedanib.
Exclusion Criteria:
- Patients with contraindications according to Summary of product characteristics (SmPC)
- Prior use of any antifibrotic treatment.
- Lack of informed consent.
- Pregnant or lactating females.
- Any physician diagnosed exacerbation of Interstitial lung disease (ILD) in the
patient's history file, irrespective of time since event.
- Current diagnosis of lung cancer.
- Respiratory failure (pH < 7,35 and/ or respiratory rate > 30/min) in the patient's
history.
- Participation in a parallel interventional clinical trial.
- Patients being spouse or lateral relatives to the second degree or economically
dependent from the investigator
Trial Details
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
Boehringer Ingelheim
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study.
N/A
Principal Investigator Affiliation
N/A
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
Industry
Overall Status
Recruiting
Countries
Bulgaria, Czechia, Poland, Romania, Switzerland
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied.
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
